Inotek Pharmaceuticals Corporation announced today that it has closed its Series B financing with the completion of the second $10 million tranche. In total, the Company raised $35 million in its Series B round. New investors in the Series B round were Caisse de depot et placement du Quebec (the “Caisse”), the largest Canadian institutional investor with over CA$100 billion of net assets under management, and Pitango Venture Capital, the largest venture capital firm in Israel with over $1 billion under management. Also participating in the Series B round were all three of the Company’s Series A investors: Care Capital LLC, Rho Ventures, and MedImmune Ventures.
